<DOC>
	<DOCNO>NCT00036387</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness Infliximab ( Remicade ) patient Rheumatoid Arthritis . Infliximab ( Remicade ) target specific proteins body 's immune system help control development inflammation help reduce pain rheumatoid arthritis .</brief_summary>
	<brief_title>A Study Safety Effectiveness Infliximab ( Remicade ) Patients With Rheumatoid Arthritis .</brief_title>
	<detailed_description>This randomize ( patient assign different treatment base chance ) , double-blind ( neither patient physician know whether drug placebo take , dosage ) trial safety anti-tumor necrosis factor ( TNF ) chimeric monoclonal antibody ( Infliximab ) combination methotrexate ( MTX ) compare methotrexate alone patient rheumatoid arthritis standard disease-modifying anti-rheumatic drug background therapy . The purpose study well understand safety occurrence infection patient treat either placebo 3 mg/kg 10 mg/kg infliximab combination methotrexate ( MTX ) . Patients receive infusion either placebo 3 10mg/kg Infliximab week 0 , 2 , 6 , 14 every 8 week week 46 . Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . Patients receive 3 to10mg/kg Infliximab ( Remicade ) placebo via infusion week 0 , 2 , 6 , 14 every 8 week week 46 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Patients must diagnosis Rheumatoid Arthritis least 3 month screen If patient childbearing potential , must use adequate birth control measure Patients must receive MTX =3 month randomization stable dose ( =25 mg/week ) =4 week randomization Patients must pregnant , nursing , plan pregnancy within 18 month enrollment Patients must rheumatic disease Rheumatoid Arthritis systemic inflammatory condition Patients must confine wheelchair Patients must treat approve investigational biologic agent except approve vaccine immunization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>infliximab</keyword>
	<keyword>anti-TNF</keyword>
	<keyword>methotrexate</keyword>
	<keyword>safety efficacy</keyword>
	<keyword>Remicade</keyword>
</DOC>